Today: 5 February 2026
Subscribe
Browse Category

NASDAQ:CAPR News 3 December 2025 - 4 December 2025

Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Capricor Therapeutics (CAPR) Soars After HOPE‑3 Win: Latest News, Analyst Targets and Stock Forecast as of December 4, 2025

Updated: December 4, 2025 – mid‑day U.S. trading Capricor Therapeutics, Inc. (NASDAQ: CAPR) has just pulled off the kind of move small‑cap biotech traders dream about and risk managers lose sleep over. After releasing decisive Phase 3 data for its Duchenne muscular dystrophy (DMD) cell therapy Deramiocel, the stock has exploded several hundred percent in barely two trading sessions and…
4 December 2025
·····
Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Capricor Therapeutics (CAPR) Stock Skyrockets on HOPE‑3 Win: FDA Path, Price Targets and 2026 Outlook

Updated December 3, 2025 Capricor Therapeutics, Inc. (NASDAQ: CAPR) has just turned into one of the wildest biotech stories of 2025. After the company reported positive topline results from its pivotal Phase 3 HOPE‑3 trial of deramiocel in Duchenne muscular dystrophy (DMD) early Wednesday, CAPR stock exploded from roughly $6.36 at Tuesday’s close to around $30 in Wednesday’s trading —…
3 December 2025
····
Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now

Capricor Therapeutics’ stock exploded higher on December 3, 2025 after the biotech announced that its pivotal Phase 3 HOPE‑3 trial of Deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD) met both its primary and key secondary endpoints. GlobeNewswire Below is a deep dive into today’s news, the regulatory backdrop, the company’s finances and pipeline, and how analysts have been thinking about…
3 December 2025
·····
Capricor Therapeutics (CAPR) Soars on Positive Phase 3 HOPE‑3 Results: Latest Stock News, Analyst Targets and 2025 Outlook

Capricor Therapeutics (CAPR) Soars on Positive Phase 3 HOPE‑3 Results: Latest Stock News, Analyst Targets and 2025 Outlook

Capricor Therapeutics, Inc. (NASDAQ: CAPR) is back in the spotlight on December 3, 2025, after announcing positive topline results from its pivotal Phase 3 HOPE‑3 trial of deramiocel (CAP‑1002) in Duchenne muscular dystrophy (DMD). The news has reignited hopes for eventual U.S. approval of the therapy and sent CAPR shares sharply higher in premarket trading. Capricor Therapeutics, Inc. With Wall…
3 December 2025
·····

Stock Market Today

  • Perseus Mining's Ongoing Buy-Back Supports Stable Production and Capital Allocation
    February 5, 2026, 10:24 AM EST. Perseus Mining (ASX:PRU) reported steady gold production of 424,989 ounces and sales of 437,022 ounces in 2025, maintaining fiscal 2026 guidance of 400,000-440,000 ounces at an All-In Site Cost (AISC) of US$1,800 per ounce. The company's active on-market share buy-back, nearing 1 million shares, underscores a disciplined capital management approach. This move may enhance earnings per share but increases scrutiny on operational execution and cost control. Market views on Perseus's valuation vary widely, reflecting uncertainty on cost performance and production outcomes. Investors are advised to monitor upcoming H1 FY26 results and any shifts in cost guidance as key catalysts. Perseus remains a low-multiple gold producer with strong liquidity and a commitment to returning capital, appealing to long-term, value-focused shareholders.
Go toTop